Multi Cancer Early Detection Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Gene Panel, LDT & Others), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global multi cancer early detection market was valued at USD 856.14 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 15.80% from 2023 to 2030. The market for multi cancer early detection (MCED) is expected to witness growth due to the factors such as the increasing prevalence of cancer and the enhanced focus of the governments on the early detection of cancers. In 2020, according to the WHO, cancer is the world's leading cause of death, accounting for nearly 10 million deaths or almost one in six deaths. Smoking, having a high body mass index, drinking, obesity, and elevated cholesterol are some of the factors that contribute to one-third of cancer-related deaths. The market offers a great opportunity with the growing awareness regarding the early detection of cancer for improving patient survival and reducing treatment costs.

Many hospitals and community health centers are working to raise screening rates. The COVID-19 pandemic has resulted in a significant decline in cancer screening rates that was brought on by the pandemic. The number of people having screenings fell dramatically in 2020 as the coronavirus pandemic spread. Other screening facilities were temporarily closed while they battled severe staffing shortages. Additionally, people were apprehensive about visiting hospitals and other healthcare facilities for non-emergency procedures due to the fear of contracting COVID-19. However, the rate of cancer screening bounced back to normal in 2021 and 2022.

The development of MCED is undergoing extensive R&D to enhance diagnostic performance. For instance, in July 2022, in association with Yorkshire Cancer Research and the University of Leeds, Elypta launched the Multi-Cancer Early Detection study to assess the levels of the metabolic GAGOme in adults at high risk for developing cancer. The study built upon proof-of-concept data presented at the American Society of Clinical Oncology conference in June 2021 showed that GAGOmes could detect one-third of all stage I cancers for 14 types of cancer, including lung and kidney.

Furthermore, the development of tests that can accurately and simultaneously screen for signs of a large number of cancers, the majority of which are currently without an efficient screening method, is expected to fuel the growth of the overall market. For instance, GENECAST, GRAIL, and Thrive Earlier Detection are significantly expanding the potential of liquid biopsy and opening up new MCED possibilities.

Although MCED tests are an emerging trend in the cancer detection and diagnosis market, one of the major challenges associated with them is the collection of adequate safety and efficacy data for regulatory approval. However, NCI and FDA are looking for evidence to study and evaluate MCED tests. The U.S. Food and Drug Administration (FDA) has been debating the evidence required to approve MCED tests as well as the possibility of including real-world data in that assessment. The organization held a public workshop in March 2020 to examine the crucial assessment questions required to assess the performance traits, safety, and clinical outcomes of MCED tests.

Type Insights

The gene panel, LDT, and others segment held the largest revenue share of 100.0% in 2022 as it provides testing for multiple cancers. Gene panels focus on the detection of hereditary cancers and the rising awareness regarding hereditary cancers is propelling the demand for genetic tests that detect cancers in the early stages to enhance the survival rates of the patients.

The liquid biopsy segment is expected to witness the fastest growth of 49.5% over the forecast period. The dominance of the segment is attributed to its high adoption and acceptance of cancer detection. Liquid biopsy is one of the emerging technologies in diagnostics. Even though scientists have known there is free-floating DNA in blood since the 1960s and have long fantasized about the possibility of diagnosing cancer through blood analysis, the World Economic Forum has named liquid biopsy as one of the top 10 emerging technologies in the world.

End-use Insights

The hospitals segment dominated the overall market with a revenue share of over 48.5% in 2022. The dominance of this segment is attributed to the presence of specialized doctors and healthcare staff that are involved in diagnosis and treatment. Hospitals serve as a medium to educate and create awareness among individuals about specific diseases and disorders. MCED is an emerging technology about which the target audience has minimal awareness. Hence, in hospitals, asymptomatic patients are tested for multiple forms, making it easier for treatment.

Diagnostic laboratories are expected to witness lucrative growth of 15.8% over the forecast period owing to increased testing and the availability of resources for performing tests. There has been an increased dependence of hospitals on diagnostic laboratories for testing and evaluation, which further leads to the accelerated growth of the segment.

Regional Insights

Europe dominated the market with a revenue share of over 36.0% in 2022. The growth of the region is attributed to the increased funding in R&D and the increased prevalence of cancer. For instance, the EU-funded DeteCTCs project seeks to accelerate the commercialization of the CellMate innovation to raise the bar for the diagnosis and treatment of cancer patients. With just one blood draw, CellMate can simultaneously identify multiple cancer types at an early stage by utilizing AI-powered bioinformatics, DNA sequencing, and advanced universal circulating cancer cell capture and recognition technology.

North America is estimated to witness the fastest growth of 20.9% over the forecast period. Researchers in the U.S. have recently begun a significant trial of a single MCED test. A significant NCI-funded trial with an undetermined start date will likely begin in the U.S. within the next 18 to 24 months and will involve several MCED tests. In addition, it is anticipated that the rising incidence of cancer in the region will fuel market expansion. For instance, according to the American Cancer Society, over 600,000 people are anticipated to die from cancer in 2021, and it is predicted that 1.9 million new cases will be diagnosed in the country. This is equivalent to roughly 1,650 fatalities every day.

Key Companies & Market Share Insights

Key players operating in the market are focusing on research and development and screening the developed detection test on a large population pool to understand and test the efficacy of the test. For instance, in July 2022, Grail, LLC declared that enrollment for the NHS-Galleri trial was completed in just under 10 months. 140,000 healthy volunteers have been enrolled in the trial, which is the largest-ever investigation of a multi-cancer early detection test.

Grail is an emerging player in the market and is undertaking multiple strategies to enhance the adoption and reach of the product by undertaking strategic initiatives. For instance, in May 2022, the U.S. Department of Veterans Affairs announced a collaboration with Grail for the screening of 10,000 veterans with the Galleri Test at 10 sites. Some prominent players in the global multi cancer early detection market include:

• Grail, LLC (Illumina, Inc.)

• Exact Sciences Corporation.

• Foundation Medicine, Inc.

• AnchorDx

• Guardant Health, Inc.

• Burning Rock Biotech Limited

• GENECAST

• Laboratory for Advanced Medicine, Inc.

• Singlera Genomics Inc.

Multi Cancer Early Detection Market Report Scope

Global Multi Cancer Early Detection Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global multi cancer early detection market report based on type, end-use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Liquid Biopsy

  • Gene Panel, LDT & Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Diagnostic Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE